Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00551200 · ClinicalTrials.gov registry record · Phase 2
Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
A Phase 2 study of Urea Cycle Disorders, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT00551200 is a Phase 2 study of Urea Cycle Disorders that has completed, run by Amgen. The registered enrollment target is 14 participants, below the 393-participant average among 4 other Urea Cycle Disorders trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00551200, a Phase 2 study of Urea Cycle Disorders, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether HPN-100 is safe and tolerable in subjects with Urea Cycle Disorders.
Conditions Studied
Interventions
- DRUG HPN-100
- DRUG BUPHENYL®
Study Locations (2)
Minnesota
- University of Minnesota - Minneapolis
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00551200
The ClinicalTrials.gov registry entry for NCT00551200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 4 other Urea Cycle Disorders trials with a reported enrollment target (96% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urea Cycle Disorders appearing as the primary indexed condition, and to 2 interventions - of which HPN-100 is the first listed.
NCT00551200 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT00551200 about?
NCT00551200 is a clinical study titled "Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders". The purpose of this study is to determine whether HPN-100 is safe and tolerable in subjects with Urea Cycle Disorders.
What is the current status of trial NCT00551200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-10. Estimated completion is 2008-12.
What conditions does trial NCT00551200 study?
This clinical trial studies the following conditions: Urea Cycle Disorders.
What interventions are being tested in trial NCT00551200?
The interventions under investigation include: HPN-100 (DRUG), BUPHENYL® (DRUG).
Who is sponsoring clinical trial NCT00551200?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00551200 being conducted?
This trial has 2 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urea Cycle Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants
COMPLETED · Phase 2
-
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
COMPLETED · Phase 2
-
Longitudinal Study of Urea Cycle Disorders
RECRUITING
-
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.